TSE:GUD

Knight Therapeutics (GUD) Stock Forecast, Price & News

C$4.91

+0.03 (+0.61%)

(As of 06/6/2023 ET)

Compare

Today's Range: C$4.82
▼
C$4.91
50-Day Range: C$4.35
▼
C$4.96
52-Week Range: C$4.28
▼
C$6.20

Volume: 124,835 shs
Average Volume: 124,759 shs
Market Capitalization: C$534.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$5.97

Profile Analyst Ratings Chart Competitors Earnings Insider Trades Headlines Social Media

Knight Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 21.5% Upside
C$5.97 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars

2.3

Analyst's Opinion

Consensus Rating
Knight Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$5.97, Knight Therapeutics has a forecasted upside of 21.5% from its current price of C$4.91.
Amount of Analyst Coverage
Knight Therapeutics has only been the subject of 3 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for GUD.

0.0

Dividend Strength

Dividend Yield
Knight Therapeutics does not currently pay a dividend.
Dividend Growth
Knight Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GUD.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Knight Therapeutics this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for GUD on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Knight Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Knight Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.23% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.91% of the stock of Knight Therapeutics is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Knight Therapeutics is -35.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Knight Therapeutics is -35.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Due to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.
Price to Book Value per Share Ratio
Knight Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Knight Therapeutics (TSE:GUD) Stock

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Receive GUD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GUD Stock News Headlines

June 2, 2023 | finance.yahoo.com

Knight to Present at the Jefferies 2023 Healthcare Conference in New York City

May 31, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc down on Wednesday (GUD)

June 6, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 26, 2023 | finance.yahoo.com

Samira Sakhia Bought 12% More Shares In Knight Therapeutics

May 26, 2023 | finance.yahoo.com

Samira Sakhia Bought 12% More Shares In Knight Therapeutics \

May 23, 2023 | finance.yahoo.com

Shareholders in Knight Therapeutics (TSE:GUD) are in the red if they invested five years ago

May 8, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc down on Monday (GUD)

May 4, 2023 | finance.yahoo.com

Notice of Knight Therapeutics' First Quarter 2023 Results Conference Call

June 6, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

April 28, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc down on Friday (GUD)

April 18, 2023 | finance.yahoo.com

Knight to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 10, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc up on Monday (GUD)

March 28, 2023 | americanbankingnews.com

Knight Therapeutics (TSE:GUD) Downgraded by National Bank Financial to "Sector Perform Market Weight"

March 27, 2023 | americanbankingnews.com

National Bankshares Trims Knight Therapeutics (TSE:GUD) Target Price to C$6.00

March 26, 2023 | americanbankingnews.com

Knight Therapeutics (TSE:GUD) Price Target Cut to C$6.50

March 25, 2023 | marketwatch.com

Knight Therapeutics Inc. ranks on The Globe and Mail's fourth-annual Women Lead Here benchmark of executive gender diversity

March 23, 2023 | finance.yahoo.com

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

March 22, 2023 | americanbankingnews.com

Knight Therapeutics (TSE:GUD) Hits New 52-Week Low at $4.92

February 28, 2023 | benzinga.com

Knight Therapeutics Stock (OTC:KHTRF), Quotes and News Summary

January 27, 2023 | nypost.com

Spielberg: ‘Dark Knight’ should’ve been Oscars’ first Best Picture blockbuster

January 18, 2023 | msn.com

Wayne Knight Claims Seinfeld 'Obliterated' His Film Career

November 8, 2022 | finance.yahoo.com

Bullish insiders bet CA$2.9m on Knight Therapeutics Inc. (TSE:GUD)

October 11, 2022 | finance.yahoo.com

Knight Therapeutics Inc. (TSE:GUD) most popular amongst individual investors who own 57%, insiders hold 20%

September 23, 2022 | finance.yahoo.com

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

September 1, 2022 | reuters.com

Knight Therapeutics Inc

August 15, 2022 | finance.yahoo.com

Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

July 12, 2022 | finanznachrichten.de

Basilea Pharmaceutica AG: Basilea announces Zevtera (ceftobiprole) marketing authorization in Brazil

See More Headlines

GUD Price History

30 days | 90 days | 365 days | Advanced Chart

GUD Company Calendar

Last Earnings: 3/23/2023
Today: 6/06/2023
Next Earnings (Estimated): 8/10/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:GUD
CUSIP: N/A
CIK: N/A
Web: www.gud-knight.com
Phone: 514-484-4483
Fax: N/A
Employees: 660
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: C$5.97
High Stock Price Forecast: C$6.50
Low Stock Price Forecast: C$5.40
Forecasted Upside/Downside: +23.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($0.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: -1013.5
Net Income: C$-15,020,000.00
Net Margins: -4.81%
Pretax Margin: N/A
Return on Equity: -1.82%
Return on Assets: -0.68%

Debt

Debt-to-Equity Ratio: 10.09
Current Ratio: 2.98
Quick Ratio: 1.79

Sales & Book Value

Annual Sales: C$312.35 million
Price / Sales: 1.69
Cash Flow: C$1.26 per share
Price / Cash Flow: 3.85
Book Value: C$7.44 per share
Price / Book: 0.65

Miscellaneous

Outstanding Shares: 108,840,000
Free Float: N/A
Market Cap: C$526.79 million
Optionable: Not Optionable
Beta: 0.52

Key Executives

Mr. Jonathan Ross Goodman B.A. (Age 53)
BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman
Comp: $455.25k

Ms. Samira Sakhia BCom (Age 54)
CA, CPA, MBA, Pres, CEO & Director
Comp: $691.66k

Mr. Arvind Utchanah
Chief Financial Officer

Ms. Amal Khouri B.Sc.
M.B.A., Chief Bus. Officer

Mr. Jeff Martens
Global VP Commercial

Mr. Leopoldo Bosano
Vice-Pres of Manufacturing & Operations

Ms. Daniela Marino
Global VP of Legal & Compliance

Ms. Susan Caroline Emblem
Global VP of HR

Ms. Jody Engel
Sr. Director of Bus. Devel.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

GUD Stock - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GUD shares.
View GUD analyst ratings or view top-rated stocks.
What is Knight Therapeutics' stock price forecast for 2023?: 2 brokerages have issued twelve-month target prices for Knight Therapeutics' stock. Their GUD share price forecasts range from C$5.40 to C$6.50. On average, they predict the company's stock price to reach C$5.97 in the next year. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for GUD or view top-rated stocks among Wall Street analysts.
How have GUD shares performed in 2023?: Knight Therapeutics' stock was trading at C$5.18 on January 1st, 2023. Since then, GUD shares have decreased by 6.6% and is now trading at C$4.84.
View the best growth stocks for 2023 here.
When is Knight Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GUD earnings forecast.
How were Knight Therapeutics' earnings last quarter?: Knight Therapeutics Inc. (TSE:GUD) released its earnings results on Thursday, March, 23rd. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $81.66 million for the quarter, compared to analyst estimates of $62 million. Knight Therapeutics had a negative trailing twelve-month return on equity of 1.82% and a negative net margin of 4.81%.
What other stocks do shareholders of Knight Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Chemtrade Logistics Income Fund (CHE.UN), Canadian National Railway (CNR), Dollarama (DOL) and Extendicare (EXE).

What is Knight Therapeutics' stock symbol?: Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."
How do I buy shares of Knight Therapeutics?: Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Knight Therapeutics' stock price today?: One share of GUD stock can currently be purchased for approximately C$4.84.
How much money does Knight Therapeutics make?: Knight Therapeutics (TSE:GUD) has a market capitalization of C$526.79 million and generates C$312.35 million in revenue each year. The company earns C$-15,020,000.00 in net income (profit) each year or C($0.14) on an earnings per share basis.
How many employees does Knight Therapeutics have?: The company employs 660 workers across the globe.
How can I contact Knight Therapeutics?: The official website for the company is www.gud-knight.com. The company can be reached via phone at 514-484-4483.

This page (TSE:GUD) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Knight Therapeutics (GUD) Stock Forecast, Price & News

Knight Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Knight Therapeutics (TSE:GUD) Stock

GUD Stock News Headlines

GUD Price History

GUD Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

GUD Stock - Frequently Asked Questions

Overall MarketRank^™